14/14: Understanding the role of autoantibodies in IIMs is crucial for effective diagnosis & management. 🩺Stay tuned for more updates on this rapidly evolving field! ⚡

13/14 Re-defining IIM into distinct endotypes could offer new insights into the heterogeneity of this complex disease & inform personalized treatment strategies. 🧬

Generate videos in just a few seconds. Try Grok Imagine, free for a limited time.

12/14: 📈 The validation & standardization of commercially available autoantibody assays with large, longitudinally followed cohorts are paramount. 🧪.

11/14: 🤔 The increasing recognition of subsets within these serological categories has underscored that much remains unknown about this complex disease. 🔬 Future research should focus on characterizing IIMs through robust global collaborations. 🌍

10/14: 🔬 Various methods are used for detecting autoantibodies in IIMs, including:. Immunoprecipitation.ELISA.Line blot assay.Mass spectrometry

9/14: While the exact role of autoantibodies in IIM pathogenesis remains unclear, emerging evidence suggests their potential involvement in muscle damage. 💪

8/14: 🧪 Novel autoantibodies have been recently identified, such as:. Anti-CCAR1 antibodies.Anti-Sp4 antibodies.Anti-CTTN antibodies.Anti-mitochondrial antibodies (AMAs).Anti-elF3 antibodies

7/14: Some MAAs commonly found in IIMs include:.*Anti-PM/Scl antibodies 🧪.*Anti-U1RNP antibodies 🧪.*Anti-Ro52 antibodies 🧪.*Anti-Ku antibodies 🧪

6/14: 🧬 ASyS is characterized by the presence of MSAs that target aminoacyl-transfer RNA synthetases (ARS). The most common autoantibody in ASyS is anti-Jo1 (anti-histidyl-tRNA synthetase). 🧪

5/14: In IMNM, the key autoantibodies are:.*Anti-SRP antibodies 🧪.*Anti-HMGCR antibodies 🧪

4/14: In dermatomyositis, the MSAs include:.*Anti-Mi2 antibodies 🧪.*Anti-MDA5 antibodies 🧪.*Anti-TIF1 antibodies 🧪.*Anti-NXP2 antibodies 🧪

3/14: 🩸MSAs are exclusively found in IIM patients, while MAAs can also be present in other autoimmune diseases. These autoantibodies target various cellular components, including nuclear & cytoplasmic elements. 🧬

2/14 The discovery of myositis-specific autoantibodies (MSAs) & myositis-associated autoantibodies (MAAs) has revolutionized our understanding of IIMs, enabling more precise diagnoses & prognostic assessments.

1/14: 🔬 Idiopathic inflammatory myopathies (IIMs) are a diverse group of autoimmune diseases characterized by chronic muscle inflammation.

RT @EVImmunoallergy: 1/12 🧫🔬.Exploring methods for IgE antibody testing: Singleplex vs. Multiplex ImmunoAssays! Dive into the latest insigh….

10/10 📊 Key Takeaways:. Personalize treatment.Regular monitoring crucial.Multi-disciplinary approach essential.New criteria aid research standardization.Stay updated on evolving management strategies!.#APS #Rheumatology.

9/10 🔍 Special Scenarios:. Check baseline PT pre-VKA.POC INR only after 3 paired results match lab.Consider anti-Xa monitoring.Careful with heparinoids

8/10 ⚡ Recurrent Thrombosis Protocol:. Check INR accuracy & TTR.Consider INR 3.0-4.0.Add antiplatelet OR.Add hydroxychloroquine.Consider rituximab in refractory cases

7/10 🧠 APS Stroke Management:. VKA (target INR 2.5) first-line.Add antiplatelet if vascular risks.Consider DAPT if VKA contraindicated.Joint care with stroke physicians

6/10 🫀 Cardiac Surgery in APS:. Baseline ACT crucial.Anti-Xa monitoring preferred.Create patient-specific ACT curve.Pre-plan post-op anticoagulation.Risk of thrombosis AND bleeding ⚠